| Full text | |
| Author(s): |
Correa, Mab Pereira
;
Costa Andrade, Frans Eberth
;
Gimenes, Alexandre Dantas
;
Gil, Cristiane Damas
Total Authors: 4
|
| Document type: | Journal article |
| Source: | JOURNAL OF MOLECULAR MEDICINE-JMM; v. 95, n. 9, p. 1005-1015, SEP 2017. |
| Web of Science Citations: | 5 |
| Abstract | |
Atopic dermatitis (AD) is caused by both dysregulated immune responses and an impaired skin barrier. Although beta-galactoside-binding protein galectin-1 (Gal-1) has immunomodulatory effects in several inflammatory disorders, therapeutic strategies based on its anti-inflammatory properties have not been explored in AD. Thus, we evaluate pharmacological treatment with Gal-1 in the progression of an ovalbumin (OVA)induced AD-like skin lesions. The skin of OVA-immunized male BALB/c mice was challenged with drops containing OVA on days 11, 14-18 and 21-24. Additionally, in the last week, a subset of animals was treated intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex). Treatment with rGal-1 decreased the clinical signs of dermatitis in BALB/c mice and diminished local eotaxin and IFN-gamma levels. The treatment also suppressed the infiltration of eosinophils and mast cells, which was verified by reduced expression of mouse mast cell protease 6 (mMCP6) and eosinophil peroxidase (EPX). These localized effects are associated with extracellular signal-regulated kinase (ERK) activation and downregulation of endogenous Gal-1. The inhibition of disease progression induced by rGal-1 was also correlated with reduced plasma IL-17 levels. Our results demonstrate that rGal-1 is an effective treatment for allergic skin inflammation in AD and may impact the development of novel strategies for skin inflammatory diseases. (AU) | |
| FAPESP's process: | 15/09858-3 - Mechanisms of action of the galectin-1 and -3 proteins in the allergic inflammation: Study in in vivo and in vitro experimental models and in allergic patients |
| Grantee: | Cristiane Damas Gil |
| Support type: | Regular Research Grants |